FIELD: pharmacology.
SUBSTANCE: invention relates to the pharmaceutical composition comprising an interferon-alpha conjugate with the polymer and the Raf inhibitor, and can be used in medicine. The received pharmaceutical composition is used for treating cancer with k-ras mutation.
EFFECT: invention provides a pharmaceutical composition having a prolonged in vivo half-life and greater anti-cancer activity than the interferon-alpha, thus reducing the introduced dose of the anticancer agent by reducing its side effects.
23 cl, 6 dwg, 5 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMPOSITION FOR NON-ALCOHOLIC FATTY LIVER DISEASE PREVENTION OR TREATMENT | 2013 |
|
RU2635966C2 |
| POLYPEPTIDE COMPLEX CONTAINING NON-PEPTIDYL POLYMER, HAVING THREE FUNCTIONAL ENDS | 2009 |
|
RU2483081C2 |
| PROTEIN COMPLEX, OBTAINED BY USING FRAGMENT OF IMMUNOGLOBULIN, AND METHOD OF SUCH COMPLEX OBTAINING | 2004 |
|
RU2356909C2 |
| LIQUID COMPOSITION OF LONG-ACTING ALPHA INTERFERON CONJUGATE | 2011 |
|
RU2613905C2 |
| IMPROVED METHOD FOR PHYSIOLOGICALLY ACTIVE POLYPEPTIDE CONJUGATE PRODUCTION | 2013 |
|
RU2639256C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING Fc-REGION OF IMMUNOGLOBULIN AS CARRIER | 2004 |
|
RU2352583C2 |
| SITE-SPECIFIC INSULIN CONJUGATE | 2014 |
|
RU2677800C2 |
| IMPROVED METHOD FOR HIGH-YIELD PRODUCTION OF PHYSIOLOGICALLY ACTIVE POLYPEPTIDE CONJUGATE | 2014 |
|
RU2677796C9 |
| PHARMACEUTICAL COMPOSITION FOR TREATING OBESITY-RELATED DISEASES CONTAINING INSULINOTROPIC PEPTIDE CONJUGATE | 2008 |
|
RU2446816C2 |
| LIQUID COMPOSITION OF LONG-ACTING INSULIN AND INSULINOTROPIC PEPTIDE | 2013 |
|
RU2643766C2 |
